Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Phanes Therapeutics
Phanes Therapeutics to Present Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
April 29, 2026
Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
April 7, 2026
Phanes Therapeutics to Present Three Clinical Posters at AACR 2026
March 18, 2026